
Sign up to save your podcasts
Or


It's estimated only one percent of medical research spending globally goes toward female-specific conditions that aren't related to cancer. But even as underfunding of women's health persists -- companies focused on women's health are innovating. Dr. Sara Naseri is working to reframe menstrual blood as a diagnostic tool rather than waste, with her company called Qvin. It received FDA clearance in January of this year for a new kind of blood test: a diagnostic menstrual pad.
Guests: Dr. Sara Naseri, CEO and co-founder of Qvin; Axios' Adriel Bettelheim
Credits: 1 big thing is produced by Niala Boodhoo, Alexandra Botti, and Jay Cowit. Music is composed by Alex Sugiura and Jay Cowit. You can reach us at [email protected]. You can send questions, comments and story ideas as a text or voice memo to Niala at 202-918-4893.
By Axios4.4
20202,020 ratings
It's estimated only one percent of medical research spending globally goes toward female-specific conditions that aren't related to cancer. But even as underfunding of women's health persists -- companies focused on women's health are innovating. Dr. Sara Naseri is working to reframe menstrual blood as a diagnostic tool rather than waste, with her company called Qvin. It received FDA clearance in January of this year for a new kind of blood test: a diagnostic menstrual pad.
Guests: Dr. Sara Naseri, CEO and co-founder of Qvin; Axios' Adriel Bettelheim
Credits: 1 big thing is produced by Niala Boodhoo, Alexandra Botti, and Jay Cowit. Music is composed by Alex Sugiura and Jay Cowit. You can reach us at [email protected]. You can send questions, comments and story ideas as a text or voice memo to Niala at 202-918-4893.

31,989 Listeners

25,763 Listeners

8,760 Listeners

3,400 Listeners

9,504 Listeners

112,032 Listeners

56,517 Listeners

10,208 Listeners

7,227 Listeners

5,455 Listeners

6,066 Listeners

6,445 Listeners

6,398 Listeners

4,365 Listeners

1,589 Listeners

617 Listeners